Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
Sales in the extended release drugs market are expected to rise at a CAGR of 11% over the forecast period 2022 to 2032. Extended-release drugs market is currently valued at US$ 48 Billion. Due to changes in prescription patterns and rising acceptance of diverse dosage forms, demand for extended-release drugs is anticipated to bolster in the forthcoming years.
Report Attribute | Details |
---|---|
Extended Release Drugs Market Size (2022) | US$ 48 Billion |
Extended Release Drugs Market Projected Growth Rate (2022 to 2032) | 11% CAGR |
Conventional drugs release the active ingredient as soon as they are administered. Drug delivery systems are planned technologies that deliver the active ingredient in a controlled environment, controlling the time, rate, and area of drug release in the body. These systems have been proven to be safe and efficient.
Extended-release drugs are a dosage formulation that reduces the dosage by half. There are specific regulations released by the FDA that extended release drugs need to comply with.
Growing adoption of various drug delivery systems by doctors and patients, safety and effectiveness of extended drug release, and a reduction in medical care expenditure due to extended-release drugs will create a conducive environment for growth in the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Compared to conventional oral drugs, extended-release drugs are well-planned administration of medication. Extended-release drugs control the time, area, and rate of the dosage, thereby increasing safety and efficacy. With the controlled release of the active ingredient, extended-release drugs also help to reduce the frequency of dosage, resulting in easier and better acceptance by patients as well as increased bioavailability.
Growing demand for pediatric and geriatric extended drug release formulations, widespread acceptance of extended drug release systems, and notable changes in the prescription pattern of doctors will drive the market.
Advancing research & development, ongoing clinical trials in the pharmaceutical sector, and a greater focus on the development of new and innovative therapeutics will further bolster the market for extended drug release.
The cost of extended drug release is a major roadblock for manufacturers. A single unit of extended-release drugs costs double or triple the conventional oral dosage. The price of Namenda's extended-release drug is around US$ 494 for 7mg. This is expected to limit sales in the market.
Conventional drugs have an almost immediate impact whereas extended-release drugs take a comparatively long time to make an impact as they have a slower course of action.
Side effects such as dose dumping could seriously affect health, which might hamper the growth of the market.
Dose dumping is the quick release of extended-release drugs in the circulatory system and can lead to toxicity. Refusal of extended-release drugs due to bad taste or swallowing difficulties is another factor that may impede demand in the forthcoming years.
Owing to the introduction of new and innovative therapeutics and their widespread acceptance, North America holds a significant share of the global extended-release drugs market. The presence of leading pharmaceutical and biopharmaceutical companies, along with increasing investments in research and development in the pharmaceutical sector will propel the growth in the North American extended-release drug market.
The growing burden of chronic diseases and the adoption of extended-release drugs in the treatment of hypertension will further underpin the demand for extended-release drugs.
Increasing adoption of extended-release drugs across countries such as Germany, the United Kingdom, Italy, and France is expected to boost the Europe extended-release market over the assessment period.
The rising incidence of chronic diseases such as COPD, diabetes, and cancer has led to quicker adoption of extended-release drugs. This is expected to create opportunities for extended-release drug manufacturers operating in Europe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
As per FMI, Asia Pacific is predicted to display the highest CAGR during the forecast period. The region has shown great potential in the extended-release drugs market due to the rapid growth of the pharmaceutical industry.
The ongoing expansion of the pharmaceutical and biopharmaceutical sectors across countries including China and India is anticipated to steer sales in the Asia Pacific extended-release drugs market.
Some of the key players in the global extended-release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy.
The global extended-release drug market is highly competitive with leading companies focusing on developing novel therapeutics. Mergers and acquisitions are the go-to strategies adopted by key players to expand their product portfolios.
Report Attribute | Details |
---|---|
Growth Rate | CAGR 11% from 2022 to 2032 |
Base Year for Estimation | 2021 |
Historical Data | 2015 to 2021 |
Forecast Period | 2022 to 2032 |
Quantitative Units | Revenue in US$ Million, and CAGR from 2022 to 2032 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Countries Covered |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
Due to the rapid growth of the pharmaceutical industry, especially in India and China, Asia Pacific is expected to emerge as an attractive market for extended-release drugs.
Leading players present in the global extended-release drug market include Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.
Rising demand for pediatric and geriatric extended-drug-release formulations and ongoing clinical trials in the pharmaceutical sector are some trends that are expected to drive sales of extended-release drugs.
1. Executive Summary | Extended Release Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and Their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyers 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Release 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Drug Release, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Drug Release, 2022 to 2032 5.3.1. Sustained Release 5.3.2. Controlled Release 5.4. Y-o-Y Growth Trend Analysis By Drug Release, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Drug Release, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distributional Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Distributional Channel, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022 to 2032 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Mail Order Pharmacies 6.3.4. Drug Stores 6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. East Asia 7.3.5. South Asia & Pacific 7.3.6. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Drug Release 8.2.3. By Distributional Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Release 8.3.3. By Distributional Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Release 9.2.3. By Distributional Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Release 9.3.3. By Distributional Channel 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Drug Release 10.2.3. By Distributional Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Release 10.3.3. By Distributional Channel 10.4. Key Takeaways 11. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.2. By Drug Release 11.2.3. By Distributional Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Release 11.3.3. By Distributional Channel 11.4. Key Takeaways 12. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Thailand 12.2.1.3. Indonesia 12.2.1.4. Malaysia 12.2.1.5. Singapore 12.2.1.6. Australia 12.2.1.7. New Zealand 12.2.1.8. Rest of South Asia & Pacific 12.2.2. By Drug Release 12.2.3. By Distributional Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Release 12.3.3. By Distributional Channel 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Drug Release 13.2.3. By Distributional Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Release 13.3.3. By Distributional Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Drug Release 14.1.2.2. By Distributional Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Drug Release 14.2.2.2. By Distributional Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Drug Release 14.3.2.2. By Distributional Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Drug Release 14.4.2.2. By Distributional Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Drug Release 14.5.2.2. By Distributional Channel 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Drug Release 14.6.2.2. By Distributional Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Drug Release 14.7.2.2. By Distributional Channel 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Drug Release 14.8.2.2. By Distributional Channel 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Drug Release 14.9.2.2. By Distributional Channel 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Drug Release 14.10.2.2. By Distributional Channel 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Drug Release 14.11.2.2. By Distributional Channel 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Drug Release 14.12.2.2. By Distributional Channel 14.13. India 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Drug Release 14.13.2.2. By Distributional Channel 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Drug Release 14.14.2.2. By Distributional Channel 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Drug Release 14.15.2.2. By Distributional Channel 14.16. Malaysia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Drug Release 14.16.2.2. By Distributional Channel 14.17. Singapore 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2021 14.17.2.1. By Drug Release 14.17.2.2. By Distributional Channel 14.18. Australia 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2021 14.18.2.1. By Drug Release 14.18.2.2. By Distributional Channel 14.19. New Zealand 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2021 14.19.2.1. By Drug Release 14.19.2.2. By Distributional Channel 14.20. GCC Countries 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2021 14.20.2.1. By Drug Release 14.20.2.2. By Distributional Channel 14.21. South Africa 14.21.1. Pricing Analysis 14.21.2. Market Share Analysis, 2021 14.21.2.1. By Drug Release 14.21.2.2. By Distributional Channel 14.22. Israel 14.22.1. Pricing Analysis 14.22.2. Market Share Analysis, 2021 14.22.2.1. By Drug Release 14.22.2.2. By Distributional Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Release 15.3.3. By Distributional Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Pfizer 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.1.5.2. Product Strategy 16.1.1.5.3. Channel Strategy 16.1.2. Mallinckrodt 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.2.5.2. Product Strategy 16.1.2.5.3. Channel Strategy 16.1.3. Actavis 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.3.5.2. Product Strategy 16.1.3.5.3. Channel Strategy 16.1.4. Janssen Pharmaceuticals 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.4.5.2. Product Strategy 16.1.4.5.3. Channel Strategy 16.1.5. Endo Pharmaceuticals 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.5.5.2. Product Strategy 16.1.5.5.3. Channel Strategy 16.1.6. Purdue Pharma 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.6.5.2. Product Strategy 16.1.6.5.3. Channel Strategy 16.1.7. Lavipharm Labs 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.7.5.2. Product Strategy 16.1.7.5.3. Channel Strategy 16.1.8. Viatris 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.8.5.2. Product Strategy 16.1.8.5.3. Channel Strategy 16.1.9. Noven 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.9.5.2. Product Strategy 16.1.9.5.3. Channel Strategy 16.1.10. Aveva 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 16.1.10.5.2. Product Strategy 16.1.10.5.3. Channel Strategy 16.1.11. Watson 16.1.11.1. Overview 16.1.11.2. Product Portfolio 16.1.11.3. Profitability by Market Segments 16.1.11.4. Sales Footprint 16.1.11.5. Strategy Overview 16.1.11.5.1. Marketing Strategy 16.1.11.5.2. Product Strategy 16.1.11.5.3. Channel Strategy 16.1.12. Impax 16.1.12.1. Overview 16.1.12.2. Product Portfolio 16.1.12.3. Profitability by Market Segments 16.1.12.4. Sales Footprint 16.1.12.5. Strategy Overview 16.1.12.5.1. Marketing Strategy 16.1.12.5.2. Product Strategy 16.1.12.5.3. Channel Strategy 16.1.13. Ranbaxy 16.1.13.1. Overview 16.1.13.2. Product Portfolio 16.1.13.3. Profitability by Market Segments 16.1.13.4. Sales Footprint 16.1.13.5. Strategy Overview 16.1.13.5.1. Marketing Strategy 16.1.13.5.2. Product Strategy 16.1.13.5.3. Channel Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 2: Global Market Volume (Tons) Forecast by Region, 2017 to 2032 Table 3: Global Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 4: Global Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 5: Global Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 6: Global Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 7: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 8: North America Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 9: North America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 10: North America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 11: North America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 12: North America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 14: Latin America Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 15: Latin America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 16: Latin America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 17: Latin America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 18: Latin America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 19: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 20: Europe Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 21: Europe Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 22: Europe Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 23: Europe Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 24: Europe Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 26: East Asia Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 27: East Asia Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 28: East Asia Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 29: East Asia Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 30: East Asia Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 31: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 32: South Asia & Pacific Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 33: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 34: South Asia & Pacific Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 35: South Asia & Pacific Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 36: South Asia & Pacific Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032 Table 37: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 38: MEA Market Volume (Tons) Forecast by Country, 2017 to 2032 Table 39: MEA Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032 Table 40: MEA Market Volume (Tons) Forecast by Drug Release, 2017 to 2032 Table 41: MEA Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032 Table 42: MEA Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Figure 1: Global Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 2: Global Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 3: Global Market Value (US$ Million) by Region, 2022 to 2032 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032 Figure 5: Global Market Volume (Tons) Analysis by Region, 2017 to 2032 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 8: Global Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 9: Global Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 12: Global Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 13: Global Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 14: Global Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 15: Global Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 16: Global Market Attractiveness by Drug Release, 2022 to 2032 Figure 17: Global Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 18: Global Market Attractiveness by Region, 2022 to 2032 Figure 19: North America Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 20: North America Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 21: North America Market Value (US$ Million) by Country, 2022 to 2032 Figure 22: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 23: North America Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 26: North America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 27: North America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 28: North America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 29: North America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 30: North America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 31: North America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 34: North America Market Attractiveness by Drug Release, 2022 to 2032 Figure 35: North America Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 36: North America Market Attractiveness by Country, 2022 to 2032 Figure 37: Latin America Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 38: Latin America Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 39: Latin America Market Value (US$ Million) by Country, 2022 to 2032 Figure 40: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 41: Latin America Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 44: Latin America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 45: Latin America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 48: Latin America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 49: Latin America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 50: Latin America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 52: Latin America Market Attractiveness by Drug Release, 2022 to 2032 Figure 53: Latin America Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 54: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 55: Europe Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 56: Europe Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 57: Europe Market Value (US$ Million) by Country, 2022 to 2032 Figure 58: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 59: Europe Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 60: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 61: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 62: Europe Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 63: Europe Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 64: Europe Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 65: Europe Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 66: Europe Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 67: Europe Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 68: Europe Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 69: Europe Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 70: Europe Market Attractiveness by Drug Release, 2022 to 2032 Figure 71: Europe Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 72: Europe Market Attractiveness by Country, 2022 to 2032 Figure 73: East Asia Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 74: East Asia Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 75: East Asia Market Value (US$ Million) by Country, 2022 to 2032 Figure 76: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 77: East Asia Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 78: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 79: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 80: East Asia Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 81: East Asia Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 82: East Asia Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 83: East Asia Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 84: East Asia Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 85: East Asia Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 88: East Asia Market Attractiveness by Drug Release, 2022 to 2032 Figure 89: East Asia Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 90: East Asia Market Attractiveness by Country, 2022 to 2032 Figure 91: South Asia & Pacific Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 92: South Asia & Pacific Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 93: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032 Figure 94: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 95: South Asia & Pacific Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 96: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 97: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 98: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 99: South Asia & Pacific Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 100: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 101: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 102: South Asia & Pacific Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 103: South Asia & Pacific Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 104: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 105: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 106: South Asia & Pacific Market Attractiveness by Drug Release, 2022 to 2032 Figure 107: South Asia & Pacific Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 108: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032 Figure 109: MEA Market Value (US$ Million) by Drug Release, 2022 to 2032 Figure 110: MEA Market Value (US$ Million) by Distributional Channel, 2022 to 2032 Figure 111: MEA Market Value (US$ Million) by Country, 2022 to 2032 Figure 112: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 113: MEA Market Volume (Tons) Analysis by Country, 2017 to 2032 Figure 114: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 115: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 116: MEA Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032 Figure 117: MEA Market Volume (Tons) Analysis by Drug Release, 2017 to 2032 Figure 118: MEA Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032 Figure 119: MEA Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032 Figure 120: MEA Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032 Figure 121: MEA Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032 Figure 122: MEA Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032 Figure 123: MEA Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032 Figure 124: MEA Market Attractiveness by Drug Release, 2022 to 2032 Figure 125: MEA Market Attractiveness by Distributional Channel, 2022 to 2032 Figure 126: MEA Market Attractiveness by Country, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports